BioMarin Announces Debt Financing for Amicus Therapeutics Acquisition
SEC 8-K Filing Notice
Company: BioMarin Pharmaceutical Inc. (BMRN) Filing Date: 2026-01-29 Accession Number: 0001193125-26-029401
Items Filed
Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Summary
BioMarin Pharmaceutical Inc. (BMRN) announced the pricing of a $850 million private offering of 5.500% senior unsecured notes due 2034. Concurrently, BioMarin completed the syndication of a new $2 billion senior secured term loan “B” facility, adding to an existing $800 million senior secured term loan “A” facility, and anticipates entering into a $600 million senior secured revolving credit facility. These financing activities are directly tied to BioMarin's pending acquisition of Amicus Therapeutics, Inc.
Key Takeaways
- BioMarin prices $850M senior unsecured notes offering at 5.500% due 2034 to fund Amicus acquisition.
- Syndication completed for a new $2B senior secured term loan “B” facility.
- Financing package includes a $800M senior secured term loan “A” facility and a $600M senior secured revolving credit facility.
- Proceeds will fund the Amicus acquisition, related fees, and expenses.
- Notes are subject to redemption if the Amicus acquisition is not completed by December 19, 2026.
Analysis
This significant debt financing underscores BioMarin's commitment to acquiring Amicus Therapeutics, a move that likely aims to expand BioMarin's portfolio and pipeline, potentially adding new revenue streams and therapeutic areas. For investors, this represents a calculated risk, as the success of the acquisition and the subsequent integration of Amicus will be crucial for BioMarin to manage its increased debt burden. Competitors in the rare disease space will be watching closely to see how this acquisition reshapes the market landscape and whether it creates new competitive pressures. The broader pharmaceutical market will observe the deal as an example of strategic consolidation within the rare disease sector.
This post was automatically generated from an SEC 8-K filing.
Sources: